STAAR Surgical Company
STAA · NASDAQ
11/5/2025 | 6/27/2025 | 3/28/2025 | 12/27/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.23 | 0.18 | -0.07 | 0.02 |
| FCF Yield | 0.14% | -3.47% | -0.82% | -0.43% |
| EV / EBITDA | 42.11 | -31.28 | -22.88 | -42.58 |
| Quality | ||||
| ROIC | 2.19% | -5.07% | -14.55% | -7.11% |
| Gross Margin | 82.21% | 74.00% | 65.76% | 64.65% |
| Cash Conversion Ratio | 0.30 | 1.62 | 0.11 | -0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.41% | -9.81% | -1.79% | 3.35% |
| Free Cash Flow Growth | 106.14% | -303.24% | -41.69% | -133.32% |
| Safety | ||||
| Net Debt / EBITDA | -5.18 | 5.57 | 4.21 | 4.13 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.32 | 0.22 | 0.30 | 0.40 |
| Cash Conversion Cycle | 295.96 | 393.72 | 316.57 | 284.10 |